Ophthotech Corp.’s (OPHT) Buy Rating Reaffirmed at BTIG Research
Ophthotech Corp. (NASDAQ:OPHT)‘s stock had its “buy” rating reaffirmed by investment analysts at BTIG Research in a research report issued on Tuesday. They currently have a $92.00 price target on the biopharmaceutical company’s stock. BTIG Research’s target price would indicate a potential upside of 57.72% from the stock’s current price.
Several other research analysts have also weighed in on OPHT. JPMorgan Chase & Co. raised Ophthotech Corp. from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $60.00 to $84.00 in a research report on Thursday, June 2nd. Zacks Investment Research raised Ophthotech Corp. from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a research report on Wednesday, June 15th. Barclays PLC reissued a “buy” rating on shares of Ophthotech Corp. in a research report on Tuesday, July 19th. Citigroup Inc. lifted their price objective on Ophthotech Corp. from $91.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Finally, Goldman Sachs Group Inc. reissued a “sell” rating and issued a $45.00 price objective on shares of Ophthotech Corp. in a research report on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $87.56.
Ophthotech Corp. (NASDAQ:OPHT) traded up 0.67% during mid-day trading on Tuesday, reaching $58.72. The company had a trading volume of 163,472 shares. The stock has a 50 day moving average price of $55.13 and a 200 day moving average price of $51.36. The company’s market capitalization is $2.09 billion. Ophthotech Corp. has a one year low of $35.72 and a one year high of $80.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ophthotech-corp-s-opht-buy-rating-reaffirmed-at-btig-research.html
Ophthotech Corp. (NASDAQ:OPHT) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.20. Ophthotech Corp. had a negative return on equity of 296.63% and a negative net margin of 271.28%. The firm earned $28.20 million during the quarter, compared to analyst estimates of $18.64 million. On average, equities analysts expect that Ophthotech Corp. will post ($4.89) earnings per share for the current fiscal year.
In other Ophthotech Corp. news, President Samir Chandrakant Patel sold 41,846 shares of Ophthotech Corp. stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $51.23, for a total transaction of $2,143,770.58. Following the completion of the transaction, the president now owns 174,992 shares in the company, valued at approximately $8,964,840.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David R. Guyer sold 24,060 shares of Ophthotech Corp. stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $52.12, for a total value of $1,254,007.20. Following the transaction, the chief executive officer now owns 56,451 shares of the company’s stock, valued at approximately $2,942,226.12. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Ophthotech Corp. by 11.7% in the second quarter. Vanguard Group Inc. now owns 2,211,545 shares of the biopharmaceutical company’s stock worth $112,855,000 after buying an additional 231,933 shares during the period. BlackRock Fund Advisors increased its position in Ophthotech Corp. by 16.3% in the second quarter. BlackRock Fund Advisors now owns 1,188,968 shares of the biopharmaceutical company’s stock worth $60,673,000 after buying an additional 166,961 shares during the period. State Street Corp increased its position in Ophthotech Corp. by 52.6% in the first quarter. State Street Corp now owns 1,078,837 shares of the biopharmaceutical company’s stock worth $45,601,000 after buying an additional 371,894 shares during the period. Franklin Resources Inc. increased its position in Ophthotech Corp. by 37.1% in the second quarter. Franklin Resources Inc. now owns 805,929 shares of the biopharmaceutical company’s stock worth $41,126,000 after buying an additional 218,227 shares during the period. Finally, Fiera Capital Corp bought a new position in Ophthotech Corp. during the second quarter worth about $37,890,000. Institutional investors and hedge funds own 93.73% of the company’s stock.
About Ophthotech Corp.
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
Receive News & Ratings for Ophthotech Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp. and related companies with MarketBeat.com's FREE daily email newsletter.